Expectations of robust efficacy from Phase I studies may be unrealistic, but spooked investors have made Vincerz’s cash flow problems even more acute.

Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.

The company remained tight-lipped on the biomarker driving high response rates for its CDK9 inhibitor SLS009 from a Phase II trial, as a Phase III interim analysis for its AML cancer vaccine galinpepimut-S draws near.

The first clearance from the US Food and Drug Administration for an over-the-counter fingertip pulse oximeter has gone to Masimo's MightySat Medical, which is now available at the company's website.